The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07823556

Enrollment

Registered

2026-09-16

Start date

2026-05-31

Completion date

2027-09-30

Last updated

2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus Nephritis (LN)

Keywords

Lupus nephritis, Transforming growth factor- beta, activity and chornicity indices, renal fibrosis, renal biopsy

Brief summary

To investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices

Detailed description

Lupus nephritis (LN) is a common consequence of systemic lupus erythematosus and renal fibrosis is considered as a terminal pathway of the persistent immune-mediated insult .Transforming growth factor beta (TGF - β) is well recognized as a key player in LN fibrosis . A various number of cellular and molecular pathways have been incriminated as key players in the development of renal fibrosis, one of the most important main players involved in renal fibrogenesis is the transforming growth factor- β (TGF-β) signaling pathway. The investigators aim in this study to investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices

Interventions

PROCEDURErenal biopsy

Kidney fibrosis will be assessed by means of needle core biopsy followed by histopathological assessment. Percutaneous kidney biopsies will be performed with ultrasonic guidance under local anaesthesia by an expert nephrologist.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* SLE patients who fulfilled EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus , having lupus nephritis. * Adult population with age group from 18 to 50 years old.

Exclusion criteria

* Patients with any other Rheumatological diseases such as other autoimmune CT diseases or vasculitides * Pregnancy. * Ongoing or previous chemotherapy treatment for cancer. * Any other causes of CKD or AKI ( acute kidney injury).

Design outcomes

Primary

Measure	Time frame	Description
renal biopsy	12 months	to test for the presence of Transforming Growth Factor- Beta (TGF- β) in renal biopsy of patients with lupus nephritis. All renal biopsies will be evaluated according to NIH activity and chronicity indices and fibrosis quantification according to IFTA score.

Secondary

Measure	Time frame	Description
clinical assessment of the patient	12 months	correlation with disease activity index "SLEDAI". .

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026